Back

Etienna Bio completes FDA INTERACT meeting for ETB-001 regenerative therapy

Verifying
  • Etienna Bio completed an FDA INTERACT meeting for ETB-001.
  • August 28, 2026, marked the meeting date for the regenerative aesthetics program.
  • ETB-001 remains unapproved and cannot begin human trials based solely on the meeting.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.